-Trevena’s morphine competitor, Oliceridine, just received negative news from the FDA Advisory Committee. The FDA PDUFA date is November 2nd, but they are likely to follow the adcom’s decision
-It also look like Trevena mislead investors by announcing they had successful meetings with the FDA, while the FDA claims they had many problems with the study-design proposed by TRVN including endpoints and statistical analyses.
-Press releases from TRVN in the past say different than the adcom documents, which many firms are taking up as class action lawsuits…especially given TRVN’s latest 8-K filing
I do not have any position in the company and this is not investment advice.
Follow me on twitter @matthewlepoire
Click to access UCM622730.pdf